These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 11122801

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The role of second-look laparotomy in the long-term survival in ovarian cancer.
    Tuxen MK, Strauss G, Lund B, Hansen M.
    Ann Oncol; 1997 Jul; 8(7):643-8. PubMed ID: 9296216
    [Abstract] [Full Text] [Related]

  • 6. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer.
    Jäger W, Adam R, Wildt L, Lang N.
    Arch Gynecol Obstet; 1988 Jul; 243(2):91-9. PubMed ID: 2456743
    [Abstract] [Full Text] [Related]

  • 7. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma.
    Sevinc A, Camci C, Turk HM, Buyukberber S.
    Oncology; 2003 Jul; 65(1):1-6. PubMed ID: 12837976
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparison of CA 125 assays with abdominopelvic computed tomography and transvaginal ultrasound in monitoring of ovarian cancer.
    Sugiyama T, Nishida T, Komai K, Nishimura H, Yakushiji M, Nishimura H.
    Int J Gynaecol Obstet; 1996 Sep; 54(3):251-6. PubMed ID: 8889633
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of beta1,4-galactosyltransferase as a potential biomarker for the detection of subclinical disease after the completion of primary therapy for ovarian cancer.
    Odunsi K, Ghamande S, Chandrasekaran EV, Ta A, Moysich KB, Driscoll D, Matta K, Lele S.
    Am J Obstet Gynecol; 2002 Sep; 187(3):575-80. PubMed ID: 12237630
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Evaluation on non invasive diagnostic tests for the second look in epithelial ovarian cancer].
    García Enguídanos A, Crespo Azanza E, Díaz Recaséns J, Lobo Samper F, Jorge Herrero JA, Sáinz de la Cuesta Abbad R.
    Rev Clin Esp; 1998 Aug; 198(8):502-5. PubMed ID: 9774878
    [Abstract] [Full Text] [Related]

  • 18. Factors influencing period of time between negative second-look laparotomy and ovarian carcinoma recurrence. Multicenter study in Poland.
    Markowska J, Wilkoszarska J, Emerich J, Debniak J, Popiela A, Pańszczak M, Kornafel J, Rossochacka B, Fisher Z, Goluda M, Małecki P.
    Eur J Gynaecol Oncol; 2000 Aug; 21(2):164-7. PubMed ID: 10843477
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year.
    Low RN, Duggan B, Barone RM, Saleh F, Song SY.
    Radiology; 2005 Jun; 235(3):918-26. PubMed ID: 15914479
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.